Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?

Area of Science:

• Oncology
• Urology

Background:

• Standard treatment for metastatic prostate cancer involves androgen-deprivation therapy (ADT).
• Oligometastatic prostate cancer represents an intermediate stage between localized and widespread metastatic disease.

Purpose of the Study:

• To review existing literature on metastasis-directed therapy (MDT) for oligometastatic prostate cancer.

Main Methods:

• Literature review of prospective and retrospective clinical trials.
• Analysis of oncologic outcomes and survival data.

Main Results:

• Prospective trials demonstrate improved ADT-free and progression-free survival with MDT.
• Retrospective studies and recent prospective trials confirm improved oncologic outcomes.
• Advancements in imaging and genomics aid patient selection for MDT.

Conclusions:

• Metastasis-directed therapy is a viable treatment option for select patients with oligometastatic prostate cancer.
• Improved patient selection strategies may lead to potential cures.